The results of the comparison were presented at the Association for Molecular Pathology (AMP) Annual Meeting & Expo, Baltimore, USA, November 2019 and the study that included 75 GBM tumor samples and 14 control samples showed that both tests were able to identify all patients with methylated MGMT promoter included in the study. The gene discussed is MGMT; the disease is glioblastoma.